Regencell Bioscience Holdings Limited (RGC)
USD 61.25
(-20.45%)
USD 61.25
(-20.45%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | - USD | 0.0% |
| 2023 | - USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 3.16 Billion USD | -1.07% |
| 2017 | 3.19 Billion USD | 2.23% |
| 2016 | 3.12 Billion USD | 4.59% |
| 2015 | 2.99 Billion USD | 0.0% |
| 2013 | 3.03 Billion USD | 7.57% |
| 2012 | 2.82 Billion USD | 0.58% |
| 2011 | 2.8 Billion USD | -2.97% |
| 2010 | 2.89 Billion USD | 4.44% |
| 2009 | 2.77 Billion USD | 0.0% |
| 2007 | 2.66 Billion USD | 2.42% |
| 2006 | 2.59 Billion USD | 5.27% |
| 2005 | 2.46 Billion USD | -0.84% |
| 2004 | 2.48 Billion USD | 0.0% |
| 2002 | 2.14 Billion USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | - USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | 0.0% |
| 2023 FY | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q4 | -2.34 Billion USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q1 | - USD | 100.0% |
| 2022 Q2 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | -2.34 Billion USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2018 FY | 3.16 Billion USD | -1.07% |
| 2018 Q2 | 861.6 Million USD | 20.34% |
| 2018 Q1 | 716 Million USD | -6.31% |
| 2017 Q4 | 764.2 Million USD | -6.94% |
| 2017 Q3 | 821.2 Million USD | 1.06% |
| 2017 Q2 | 812.6 Million USD | 0.14% |
| 2017 Q1 | 811.5 Million USD | 3.26% |
| 2017 FY | 3.19 Billion USD | 2.23% |
| 2016 Q4 | 785.9 Million USD | -0.15% |
| 2016 FY | 3.12 Billion USD | 4.59% |
| 2016 Q3 | 787.1 Million USD | -7.2% |
| 2016 Q2 | 848.2 Million USD | 16.99% |
| 2016 Q1 | 725 Million USD | -15.97% |
| 2015 FY | 2.99 Billion USD | 0.0% |
| 2015 Q4 | 862.8 Million USD | 24.81% |
| 2015 Q2 | 799.1 Million USD | 15.18% |
| 2015 Q3 | 691.3 Million USD | -13.49% |
| 2015 Q1 | 693.8 Million USD | -9.93% |
| 2014 Q4 | 770.3 Million USD | 5.97% |
| 2014 Q2 | 739.9 Million USD | -9.0% |
| 2014 Q1 | 813.1 Million USD | -3.47% |
| 2014 Q3 | 726.9 Million USD | -1.76% |
| 2013 Q4 | 842.3 Million USD | 31.04% |
| 2013 FY | 3.03 Billion USD | 7.57% |
| 2013 Q2 | 723.1 Million USD | 4.36% |
| 2013 Q1 | 692.9 Million USD | -4.2% |
| 2013 Q3 | 642.8 Million USD | -11.1% |
| 2012 Q4 | 723.3 Million USD | 5.61% |
| 2012 FY | 2.82 Billion USD | 0.58% |
| 2012 Q1 | 743.6 Million USD | -1.29% |
| 2012 Q2 | 613.9 Million USD | -17.44% |
| 2012 Q3 | 684.9 Million USD | 11.57% |
| 2011 Q3 | 570.9 Million USD | -13.63% |
| 2011 FY | 2.8 Billion USD | -2.97% |
| 2011 Q1 | 696.4 Million USD | -49.63% |
| 2011 Q2 | 661 Million USD | -5.08% |
| 2011 Q4 | 753.3 Million USD | 31.95% |
| 2010 Q1 | 674 Million USD | -14.58% |
| 2010 FY | 2.89 Billion USD | 4.44% |
| 2010 Q4 | 1.38 Billion USD | 92.28% |
| 2010 Q3 | 719 Million USD | -6.09% |
| 2010 Q2 | 765.6 Million USD | 13.59% |
| 2009 Q2 | 711 Million USD | -6.2% |
| 2009 Q3 | 665 Million USD | -6.47% |
| 2009 Q1 | 758 Million USD | 12.13% |
| 2009 FY | 2.77 Billion USD | 0.0% |
| 2009 Q4 | 789 Million USD | 18.65% |
| 2008 Q1 | 753 Million USD | 10.25% |
| 2008 Q4 | 676 Million USD | 7.99% |
| 2008 Q3 | 626 Million USD | 4.33% |
| 2008 Q2 | 600 Million USD | -20.32% |
| 2007 FY | 2.66 Billion USD | 2.42% |
| 2007 Q1 | 676 Million USD | -1.17% |
| 2007 Q2 | 653 Million USD | -3.4% |
| 2007 Q3 | 625 Million USD | -4.29% |
| 2007 Q4 | 683 Million USD | 9.28% |
| 2006 Q2 | 668 Million USD | 6.37% |
| 2006 Q3 | 585 Million USD | -12.43% |
| 2006 FY | 2.59 Billion USD | 5.27% |
| 2006 Q4 | 684 Million USD | 16.92% |
| 2006 Q1 | 628 Million USD | -2.35% |
| 2005 Q4 | 643.1 Million USD | 11.46% |
| 2005 FY | 2.46 Billion USD | -0.84% |
| 2005 Q1 | 611.3 Million USD | 359.62% |
| 2005 Q2 | 1.85 Billion USD | 203.78% |
| 2005 Q3 | 577 Million USD | -68.93% |
| 2004 Q3 | 540 Million USD | -70.97% |
| 2004 Q1 | 629 Million USD | 424.17% |
| 2004 Q2 | 1.86 Billion USD | 195.71% |
| 2004 Q4 | 133 Million USD | -75.37% |
| 2004 FY | 2.48 Billion USD | 0.0% |
| 2003 Q4 | 120 Million USD | -77.27% |
| 2003 Q2 | 1.56 Billion USD | 174.78% |
| 2003 Q3 | 528 Million USD | -66.35% |
| 2003 Q1 | 571 Million USD | -5.93% |
| 2002 FY | 2.14 Billion USD | 0.0% |
| 2002 Q4 | 607 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 100.0% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 100.0% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 100.0% |
| Cosmos Health Inc. | 53.37 Million USD | 100.0% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | 100.0% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 100.0% |
| Cronos Group Inc. | 88.84 Million USD | 100.0% |
| Incannex Healthcare Limited | 12 Thousand USD | 100.0% |
| Kala Pharmaceuticals, Inc. | - USD | NaN% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 100.0% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 100.0% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 100.0% |
| SCYNEXIS, Inc. | 140.14 Million USD | 100.0% |
| Safety Shot Inc | 202.67 Thousand USD | 100.0% |
| Theratechnologies Inc. | 81.76 Million USD | 100.0% |
| Alpha Teknova, Inc. | 36.68 Million USD | 100.0% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 100.0% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 100.0% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 100.0% |
| Dynavax Technologies Corporation | 232.28 Million USD | 100.0% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 100.0% |
| Radius Health, Inc. | 2.88 Billion USD | 100.0% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | 100.0% |
| Alvotech | 91.43 Million USD | 100.0% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 100.0% |
| SIGA Technologies, Inc. | 139.91 Million USD | 100.0% |
| Shineco, Inc. | 9.8 Million USD | 100.0% |
| Silver Spike Investment Corp. | 11.72 Million USD | 100.0% |
| Journey Medical Corporation | 79.18 Million USD | 100.0% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | 100.0% |
| Embecta Corp. | 1.12 Billion USD | 100.0% |
| Harrow Health, Inc. | 130.19 Million USD | 100.0% |
| Procaps Group, S.A. | 409.92 Million USD | 100.0% |
| Biofrontera Inc. | 34.07 Million USD | 100.0% |
| DURECT Corporation | 8.54 Million USD | 100.0% |
| PainReform Ltd. | - USD | NaN% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 100.0% |
| OptiNose, Inc. | 70.98 Million USD | 100.0% |
| RedHill Biopharma Ltd. | 6.51 Million USD | 100.0% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 100.0% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 100.0% |
| ProPhase Labs, Inc. | 44.38 Million USD | 100.0% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 100.0% |
| Procaps Group S.A. | 409.92 Million USD | 100.0% |
| TherapeuticsMD, Inc. | 1.3 Million USD | 100.0% |
| Viatris Inc. | 15.42 Billion USD | 100.0% |
| Rockwell Medical, Inc. | 83.61 Million USD | 100.0% |
| Aytu BioPharma, Inc. | 81 Million USD | 100.0% |
| Tilray Brands, Inc. | 788.94 Million USD | 100.0% |
| PetIQ, Inc. | 1.1 Billion USD | 100.0% |
| Talphera, Inc. | 651 Thousand USD | 100.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 100.0% |
| Alimera Sciences, Inc. | 80.75 Million USD | 100.0% |
| Assertio Holdings, Inc. | 152.06 Million USD | 100.0% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | NaN% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 100.0% |
| Hempacco Co., Inc. | 4.04 Million USD | 100.0% |
| Alvotech | 91.43 Million USD | 100.0% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 100.0% |
| Kamada Ltd. | 144.75 Million USD | 100.0% |
| Currenc Group, Inc. | 53.25 Million USD | 100.0% |
| Indivior PLC | 1.09 Billion USD | 100.0% |
| Evoke Pharma, Inc. | 5.18 Million USD | 100.0% |
| Flora Growth Corp. | 76.07 Million USD | 100.0% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | 100.0% |
| Evolus, Inc. | 202.08 Million USD | 100.0% |
| HUTCHMED (China) Limited | 837.99 Million USD | 100.0% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 100.0% |
| Akanda Corp. | 2.16 Million USD | 100.0% |